GlassScriptPhysician profile
Frank Joseph Ferritto
NPI 1295780849
$89,876.46
in general payments reported to CMS, 2019-2025
33 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,492 · 2022: $26K · 2023: $16K · 2024: $17K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $12K · Honoraria: $12K · Travel and Lodging: $2,146 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,446.00 |
| Food and Beverage | $12,094.90 |
| Honoraria | $11,900.00 |
| Travel and Lodging | $2,146.49 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $56,371.10 | 2021-2025 | |
| Organon LLC | $13,587.05 | 2025 | Vtama |
| Epi Health, LLC | $4,186.03 | 2021-2022 | |
| Genzyme Corporation | $3,682.81 | 2021-2025 | |
| Janssen Biotech, INC. | $1,795.18 | 2021-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $1,268.33 | 2021-2025 | Winlevi, Absorica Ld, Levulan Kerastick |
| E.R. Squibb & Sons, L.L.C. | $1,231.68 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $1,139.42 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $841.08 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $711.65 | 2023-2024 | Vtama |
| Almirall LLC | $686.93 | 2021-2024 | Klisyri |
| Novartis Pharmaceuticals Corporation | $546.21 | 2021-2025 | |
| Lilly USA, LLC | $501.63 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $469.11 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $404.80 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $378.49 | 2021-2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $330.19 | 2021-2024 | Arazlo, Cabtreo |
| Galderma Laboratories, L.P. | $309.14 | 2021-2025 | Nemluvio, Aklief |
| Incyte Corporation | $287.62 | 2021-2025 | Opzelura |
| Journey Medical Corporation | $242.44 | 2022-2023 | |
| Arcutis Biotherapeutics, INC. | $156.91 | 2023-2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $137.75 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $100.76 | 2022 | |
| Mayne Pharma Commercial LLC | $80.69 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $73.68 | 2021-2022 | |
| Organogenesis INC. | $63.47 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.98 | 2023-2024 | Cyltezo |
| Vyne Pharmaceuticals INC. | $58.54 | 2021 | |
| Biofrontera INC. | $50.33 | 2021-2024 | Rhodoled Xl, Ameluz, Xepi |
| Genentech USA, INC. | $43.42 | 2023-2024 | Erivedge, Xolair |
| Botanix Sb INC | $43.35 | 2025 | Sofdra |
| Dermira, INC. | $19.06 | 2021 | |
| Lnhc, INC | $16.63 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Ferritto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.